Combination therapy for malaria: the way forward?

Area of Science:

• Tropical Medicine
• Infectious Diseases
• Parasitology

Background:

• Malaria poses a significant health and economic burden in tropical regions.
• Emergence of drug-resistant Plasmodium falciparum strains is a major obstacle to malaria control.
• Combination therapy is a proven strategy for combating drug resistance in diseases like HIV/AIDS and tuberculosis.

Purpose of the Study:

• To evaluate the effectiveness of artemisinin derivative and mefloquine combination therapy in combating malaria.
• To assess the dual impact of this combination on preventing drug resistance and interrupting malaria transmission.
• To propose a new strategic approach for antimalarial drug deployment.

Main Methods:

• Large-scale field trials were conducted.
• The study involved combining an artemisinin derivative with a partner drug (mefloquine) having an unrelated mode of action.
• Evaluation of the combination's effects on parasite resistance and transmission.

Main Results:

• The drug combination demonstrated a significant "double effect."
• Prevention of the emergence and spread of drug resistance was observed.
• Interruption of Plasmodium falciparum transmission was achieved.

Conclusions:

• Combination therapy with artemisinin derivatives and partner drugs like mefloquine offers a promising new strategy for malaria chemotherapy.
• This approach, combined with early detection and confirmed diagnosis, is essential for "Rolling Back" malaria.
• Substantial economic assistance is required to manage the estimated 500 million annual malaria cases effectively.